Seawolf Therapeutics, a San Diego startup aiming to deliver DNA without viruses, has emerged from stealth with $100 million in financing and a partnership with Sanofi. The company’s TRIDENT platform uses lipid nanoparticle delivery to bring engineered DNA into the nucleus, with the goal of enabling repeat dosing—an area where classic viral vectors have fundamental limits. Backers include Versant Ventures and Eli Lilly, alongside other biotech and venture investors. Seawolf says its system supports durable expression in primate studies and positions its lead metabolic disease program for next-stage development while expanding collaborations with Sanofi. For the gene therapy market, the funding round adds to momentum around non-viral delivery modalities and reinforces investor appetite for platforms that may reduce immunogenicity constraints that affect redosing strategies.
Get the Daily Brief